All In Biotech

Drug Trial Radar · NCT04747197

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Last checked: Nov 20, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Jan 20, 2021

Primary completion

May 11, 2022

Study completion May 11, 2022

Sponsor

Lead sponsor
EyePoint Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age Related Macular Degeneration (wAMD)

Conditions

  • Wet Age-related Macular Degeneration

Interventions

  • EYP-1901Drug

    Intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular (study eye) and systemic treatment emergent adverse events (TEAEs)Time frame: Week 48

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • EyePoint Investigational Site

    Phoenix, Arizona

  • EyePoint Investigational Site

    Beverly Hills, California

  • EyePoint Investigative Site

    Mountain View, California

  • EyePoint Investigational Site

    Oxnard, California

  • EyePoint Investigational Site

    Melbourne, Florida

  • EyePoint Investigational Site

    St. Petersburg, Florida

  • EyePoint Investigational Site

    Springfield, Massachusetts

  • EyePoint Investigative Site

    Asheville, North Carolina

  • EyePoint Investigational Site

    Philadelphia, Pennsylvania

  • EyePoint Investigational Site

    Abilene, Texas

  • EyePoint Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.